Shanghai, China

Yipan Wu

This inventor holds 2 USPTO granted patents. Top assignees: Shanghai Mabgeek Biotech. Co., Ltd, Shanghai Mabgeek Biotech. Co., Ltd.. Active years: 2024-2026.


% Patents Active = 50.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2024-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Yipan Wu: Innovator in Biotech

Introduction

Yipan Wu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work focuses on innovative solutions for medical challenges, showcasing his expertise and dedication to advancing healthcare.

Latest Patents

Yipan Wu holds a patent for an "Anti-human MASP-2 antibody, preparation method therefor and application thereof." This invention discloses an antibody that can bind to human MASP-2, which plays a crucial role in the immune response. The anti-human MASP-2 antibody demonstrates good biological activity by inhibiting the cleavage of C4 and the generation of C3b. This innovation has potential applications in treating MASP-2 related diseases, such as IgA nephropathy.

Career Highlights

Yipan Wu is currently associated with Shanghai Mabgeek Biotech Co., Ltd. His role in the company allows him to leverage his expertise in antibody development and contribute to groundbreaking research in the biotech sector. His innovative approach and commitment to scientific advancement have positioned him as a key player in his field.

Collaborations

Yipan Wu collaborates with talented professionals in his company, including Shun Hu and Yang Wang. These collaborations enhance the research and development efforts at Shanghai Mabgeek Biotech, fostering an environment of innovation and teamwork.

Conclusion

Yipan Wu's contributions to biotechnology, particularly through his patent on the anti-human MASP-2 antibody, highlight his role as an influential inventor. His work not only advances scientific knowledge but also holds promise for improving patient outcomes in related diseases.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…